Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome

Regenxbio (NASDAQ: RGNX ) is a clinical-stage biopharmaceutical company focusing on gene therapies. Founded in 2008, the core technology of the company is the delivery of rescue genes using AAV payload. A growing number of approved drugs are based on thisAt ELAM1, we empower financial professionals and investors with the scientific and clinical expertise required to navigate the complexities of the healthcare sector. By bridging the gap between cutting-edge science and financial strategy, we help our client ...